Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized neoadjuvant chemotherapy for triple-negative breast cancer
NL-OMON50609Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, cyclophosphamide, carboplatin and thiotepa in triple-negative breast cancer (TNBC) (4 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Average Neoadjuvant Response Index. Started Feb 2010; status: recruiting.
02
Drugs
doxorubicincyclophosphamidecarboplatinthiotepa
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON50609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50609.